ALNA stock is trading in the pre-market on NASDAQ at USD 0.075, up roughly 3.16% from the prior close on unusually high volume. The move follows sustained retail interest and newsflow in the biotech sector that keeps penny biotech names active. Allena Pharmaceuticals, Inc. (ALNA) remains a speculative play tied to clinical progress for lead candidate ALLN-346 and balance-sheet runway. In this pre-market most-active snapshot we break down the trading picture, financial metrics, Meyka AI grade, and a model-based forecast for investors and active traders.

ALNA stock market snapshot and intraday flow

ALNA stock opened pre-market at USD 0.0641 and is trading near USD 0.075 with a one-day range of USD 0.06 to USD 0.1459. Volume is elevated at 252,311,606 shares, far above normal reported levels, signaling heavy trading interest. The price change today is +0.0023 USD or +3.16% versus the prior close of USD 0.0727. This intraday volatility is typical for low-price biotech names on NASDAQ in the United States and creates both trading opportunities and execution risk for most-active strategies.

Business overview and clinical catalysts for Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. (ALNA) is a US biotechnology company developing oral enzyme therapeutics, led by ALLN-346 for hyperuricemia and gout in patients with advanced chronic kidney disease. The company has about 120 full-time employees and is based in Newton, Massachusetts. Upcoming clinical readouts, enrollment updates, or regulatory communications are the primary fundamental catalysts that could move ALNA stock materially. Absent positive trial news, price moves are often driven by liquidity, retail flow, and sector sentiment.

ALNA financials, valuation metrics and balance-sheet snapshot

Allena’s trailing metrics show operating losses with EPS of -0.64 and a negative PE. Key ratios: current ratio 2.11, cash per share USD 0.92, and book value per share USD 0.58. Enterprise value is reported negative in the data set, reflecting small market cap reporting and data limits. Revenue per share is 0.00 and free cash flow per share is -1.43. These figures underline a development-stage biotech profile—no product revenue and continued cash burn.

Meyka AI grade and technical trading considerations

Meyka AI rates ALNA with a score out of 100: Score: 62.64 | Grade: B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus and fundamentals. For traders, notable technical points include very high intraday volume, a wide daily range, and missing 50/200-day average data in the feed. Short-term liquidity is high today, but bid-ask spreads and execution risk remain for market orders on NASDAQ.

Risks, sector context and what moves ALNA stock

ALNA operates in the Biotechnology subsector of Healthcare, which remains sensitive to clinical trial outcomes, FDA commentary, and capital markets conditions. Primary risks include trial failure, dilution from fundraising, and persistent negative earnings. Sector rotation into or out of small-cap biotech can amplify moves in ALNA stock. Given the company’s cash burn, dilution risk rises if development milestones are missed or capital markets tighten.

Price targets, analyst context and Meyka AI forecast

There are no broad sell-side consensus targets publicly available for Allena. Meyka AI’s forecast model projects a 12-month central case price of USD 0.25. Versus the current price of USD 0.075, that implies an upside of +233.33%. A conservative short-term model target is USD 0.10 (implied upside +33.33%). Forecasts are model-based projections and not guarantees. Traders should weigh these model outputs against clinical timelines and dilution risk.

Final Thoughts

Key takeaways for ALNA stock: the pre-market session on 03 Mar 2026 shows USD 0.075 per share with very high volume (252,311,606 shares), marking ALNA as one of the most active NASDAQ biotech tickers this session. Fundamentals show development-stage losses (EPS -0.64), a solid current ratio (2.11) and USD 0.92 cash per share, but also significant free cash flow deficit. Meyka AI’s proprietary grade gives ALNA a B (62.64) and a neutral HOLD suggestion based on benchmark and sector comparisons. Meyka AI’s forecast model projects a 12-month central case of USD 0.25, an implied upside of +233.33% versus the current USD 0.075; the short-term model target is USD 0.10 (+33.33%). Forecasts are model-based projections and not guarantees. For most-active traders, the combination of heavy volume and biotech catalysts offers trade setups, but the stock carries high volatility and dilution risk. Monitor clinical updates, company statements, and sector flows before taking a position. For deeper ticker tracking see the Meyka AI stock page for ALNA and regulatory filings.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.